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Abstract 
Endometrial cancer is one of the most common malignancies in the female genital tract. Programmed cell death 5 
(PDCD5) is a newly identified apoptosis related gene and plays an important role in the development of some human 
tumors. However, the expression and clinical significance of PDCD5 in endometrial cancer have not been fully eluci-
dated. Here, we evaluated the expression of PDCD5 in endometrioid endometrial carcinoma and control endome-
trium by qRT-PCR, western blot and immunohistochemistry, and analyzed the associations of PDCD5 expression with 
clinicopathological parameters of patients. In addition, we detected the expression of PDCD5 in control endometrial 
glandular epithelial cells and endometrioid endometrial carcinoma-derived cell line KLE by immunocytochemistry. 
The results showed that PDCD5 protein mainly expressed in the cytoplasm of glandular epithelial cells and endo-
metrial carcinoma cells, and there was a low level of PDCD5 expression in the nuclei of the above cells. Furthermore, 
PDCD5 protein level was significantly lower in endometrial carcinoma samples than that in control endometrium. 
The decreased PDCD5 expression was correlated with the tumor differentiation degree. It is clear that PDCD5 protein 
expression was lower in middle and low differentiated endometrial carcinoma compared with control endometrium 
and high differentiated endometrial carcinoma. However, there were no significant differences of PDCD5 expression 
between the proliferative phase and the secretory phase of control endometrium, as well as between high differenti-
ated endometrial carcinoma and controls. The results were verified in control glandular epithelial cells and KLE cells by 
immunocytochemistry. Therefore, PDCD5 may play a key role in the pathogenesis of endometrial cancer and may be 
a novel target for diagnosis and treatment of endometrial cancer.
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Background
Programmed cell death 5 (PDCD5) is a novel apopto-
sis accelerating gene which was first identified from the 
leukaemic cell clone TF-1 cells undergoing apoptosis 
in Human Disease Gene Center of Peking University. 
Therefore, it is also called TF-1 cell apoptosis-related 
gene 19 (TFAR19) (Liu et al. 1999). It has been reported 
that PDCD5 promotes DNA damage-induced apoptosis 
by interacting with Tip60 (a histone acetyltransferase) 
(Xu et  al. 2009), and PDCD5 phosphorylation induced 
by a multifunctional kinase CK2 is an important pro-
cess for its apoptotic potential (Salvi et  al. 2009). The 
functions of PDCD5 are also related to tumor sup-
pressor gene P53. Park et  al. reported YY1-associated 
factor 2 (YAF2) interacts with PDCD5 and promotes 
TP53-mediated genotoxic stress response via stabiliza-
tion of PDCD5. OTU deubiquitinase (OTUD5) binds 
to PDCD5  in  response  to etoposide treatment and 
effectively mediates the sequential activation of both 
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PDCD5 and P53 (Park et  al. 2015a, b). Xu et  al. found 
that PDCD5 interacts with p53 and functions as a posi-
tive regulator in the p53 pathway (Xu et  al. 2012b). 
Choi et al. demonstrated that PDCD5 selectively medi-
ates HDAC3 dissociation from p53, which induces 
HDAC3 cleavage and ubiquitin-dependent proteaso-
mal degradation (Choi et al. 2015). Cui et al. suggested 
that the expression of PDCD5 is negatively regulated 
by DNAJB1 and DNAJB1 targets PDCD5 to suppress 
p53-dependent apoptosis of cancer cells (Cui et  al. 
2015). The studies have confirmed that PDCD5 also sup-
presses tumorigenesis by inhibiting the Ras/Raf/MEK/
ERK signaling pathway in the human osteosarcoma cell 
line MG-63 (Han et  al. 2012) and adenovirus carrying 
PDCD5 gene exerts potent antitumor efficacy on com-
mon human leukemic cell lines (Xie et al. 2009). In addi-
tion, the downregulation of PDCD5 has been observed 
in multiple types of cancers, such as breast cancer 
(Hedenfalk et al. 2001), ovarian carcinoma (Zhang et al. 
2011), gastric cancer (Yang et  al. 2006), hepatocellular 
carcinoma (Fu et  al. 2013; Xu et  al. 2001), acute and 
chronic myeloid leukemia (Ruan et al. 2006), glioma (Li 
et al. 2008) and laryngeal squamous cell carcinoma (Xu 
et al. 2013), and correlates with tumor progression and 
prognosis. PDCD5 can also enhances chemosensitivity 
of tumor cells (Wang et  al. 2013; Xu et  al. 2012a), and 
negatively regulates inflammation in autoimmune dis-
eases (Xiao et al. 2013, 2015a, b). These findings suggest 
that apoptosis-related gene PDCD5 could be acted as 
tumor suppressor gene and inflammation-relative gene, 
and play important roles in the pathogenesis of cancers 
and inflammatory diseases.
Endometrial cancer is one of the most common malig-
nancies in female reproductive system (Horn et al. 2007; 
Wang et al. 2012). Epidemiologic studies show that some 
risk factors, including advanced age, early menarche, late 
menopause, nulliparity, long-term use of estrogen, obe-
sity and diabetes, are associated with an increased risk 
of endometrial cancer (Purdie and Green 2001). The vast 
majority of endometrial cancers are carcinomas which 
originate from the single layer of epithelial cells. Endo-
metrial carcinomas are broadly organized into two cat-
egories, Type I and Type II, based on clinical features and 
pathogenesis. Type I endometrial carcinomas occur most 
commonly before and around the time of menopause, 
and represent 75–90  % of endometrial cancer. They are 
often endometrioid carcinomas, estrogen-dependent, 
and have a favorable treatment outcome. Type II endome-
trial carcinomas usually occur in older, post-menopausal 
people. They are often non-endometrioid carcinomas 
(such as serous carcinoma, clear cell carcinoma and 
mucinous carcinoma etc.), estrogen-independent and 
carry a poorer prognosis (Sherman 2000; Bokhman 1983; 
Hecht and Mutter 2006; Emons et  al. 2000). Nowadays, 
numerous tumor suppressor genes and oncogenes, such 
as PTEN and K-ras have been reported to be involved in 
the development of endometrial cancer (Arafa et al. 2010; 
Ellis and Ghaem-Maghami. 2010; Honkavuori-Toivola 
et al. 2012; Angioli et al. 2013). However, the expression 
of PDCD5 and its clinical significance in endometrial 
cancer have not been fully elucidated.
In the present study, we investigated the levels of 
PDCD5 expression by qRT-PCR, western blot, immuno-
histochemistry and immunocytochemistry in endome-
trioid endometrial carcinoma and control endometrium 
tissues, as well as control endometrial glandular epi-
thelial cells and endometrial cancer cell line KLE. Fur-
thermore, we analyzed the associations of PDCD5 
expression with clinical and pathological characteristics 
of patients with endometrioid endometrial carcinoma. 
The results showed that PDCD5 protein expression was 
decreased in endometrioid endometrial carcinoma tis-
sues and correlated with the degree of tumor differen-
tiation, suggesting that PDCD5 could participate in the 
development and progression of endometrioid endome-
trial carcinoma.
Results
The expression levels of PDCD5 mRNA in control 
endometrium and endometrioid endometrial carcinoma 
tissues detected by qRT‑PCR
In order to study the roles of PDCD5 in endometri-
oid endometrial carcinoma, we firstly detected PDCD5 
mRNA expression in 16 freshly frozen endometrioid 
endometrial carcinoma tissues and 17 control endome-
trium using qRT-PCR. The results showed that there 
were no significant differences in PDCD5 mRNA expres-
sion between endometrioid endometrial carcinoma tis-
sues and control endometrium (P > 0.05) (Fig. 1).
The expression levels of PDCD5 protein in control 
endometrium and endometrioid endometrial carcinoma 
tissues detected by western blot
To further explore the expression status of PDCD5 in 
endometrioid endometrial carcinoma, we detected the 
levels of PDCD5 protein in 16 freshly frozen endometri-
oid endometrial carcinoma tissues and 17 control endo-
metrium using western blot. The data showed that the 
expression of PDCD5 protein in endometrioid endome-
trial carcinoma tissues was significantly lower than that 
in control endometrium, which was inconsistent with the 
results of qRT-PCR (P < 0.001) (Fig. 2a, b).
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The expression levels of PDCD5 protein in control 
endometrium and endometrioid endometrial carcinoma 
tissues detected by IHC
To verify the results of western blot, we next deter-
mine the levels of PDCD5 protein expression in 51 
endometrioid endometrial carcinoma tissues and 53 
control endometrium using IHC staining. In accord-
ance with the results of western blot, the levels of 
PDCD5 protein were significantly decreased in endo-
metrioid endometrial carcinoma tissues compared 
with control endometrium (P  <  0.01) (Figs.  3a–e, 4a), 
which suggested that the levels of PDCD5 mRNA and 
protein are inconsistent in endometrioid endometrial 
carcinoma tissues.
The endometrial lining undergoes cyclic regeneration 
and displays menstrual cycle (proliferative, secretory and 
menstrual phase) under the influence of estrogen and 
progesterone. Among 53 cases of control endometrium, 
30 cases were proliferate phase, 23 cases were secretory 
phase. However, our results showed that there were no 
significant differences in PDCD5 expression between 
proliferative phase and secretory phase of the control 
endometrium (P > 0.05) (Figs. 3a, b, 4b).
In addition, endometrioid endometrial carcinoma 
is divided into three types, such as high differentiation, 
middle differentiation and low differentiation accord-
ing to their differentiation degree. Therefore, we further 
analyzed the differences in PDCD5 protein expression 
between control endometium and high differentiation or 
middle-low differentiation of endometrioid endometrial 
carcinoma samples. The results showed that PDCD5 pro-
tein expression was significantly decreased in middle-low 
differentiation of endometrioid endometrial carcinoma 
tissues compared with control endometrium (P < 0.001), 
but there was no obvious difference between high differ-
entiation of endometrioid endometrial carcinoma tissues 
and control endometrium (Figs. 3a–e, 4c).
The expression sites of PDCD5 protein in control 
endometrium and endometrioid endometrial carcinoma 
tissues
The results from IHC revealed PDCD5 protein was mainly 
located in the cytoplasm of the control endometrial glan-
dular cells or endometrioid endometrial carcinoma cells, 
and there was also a low level of PDCD5 expression in the 
nuclei of these cells (Fig.  3a–e). In order to further con-
firm the results, we isolated and identified control endo-
metrial glandular cells and stromal cells, and then detected 
the PDCD5 expression in control endometrial glandular 
epithelial cells and stromal cells, as well as endometrioid 
endometrial carcinoma cell line KLE. The results showed 
that stromal cells expressed vimentin and glandular epithe-
lial cells expressed cytokeratin (Figs. 5a, b). More impor-
tantly, we found that PDCD5 positive staining was indeed 
mainly located in the cytoplasm of control endometrial 
glandular epithelial cells and KLE cells, and weak PDCD5 
expression was also found in the nuclei of the above cells. 
However, no obvious positive staining could be observed 
in stromal cells. Furthermore, PDCD5 protein expression 
in KLE cells was weaker than that in control endometrial 
glandular epithelial cells (Fig. 5c, d).
Fig. 1 The expression of PDCD5 mRNA in endometrioid endometrial 
carcinoma and control endometrium detected by qRT-PCR. The levels 
of PDCD5 mRNA in freshly frozen endometrioid endometrial carci-
noma and control endometrium were detected by qRT-PCR. Data 
were normalized to GAPDH. There were no significant differences 
between the two groups (P > 0.05)
Fig. 2 The expression of PDCD5 protein in endometrioid endometrial carcinoma and control endometrium detected by western blot. a The levels 
of PDCD5 protein in freshly frozen endometrioid endometrial carcinoma and control endometrium were detected by western blot. β-actin was 
used as control. b The expression of PDCD5 protein was significantly lower in endometrioid endometrial carcinoma tissues than that in control 
endometrium (P < 0.001). ***P < 0.001
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The associations of PDCD5 protein expression 
in endometrioid endometrial carcinoma tissues 
with clinicopathologic parameters of patients
In order to explore the clinical significance of PDCD5 
expression in endometrioid endometrial carcinoma, 
we analyzed the relationships between PDCD5 expres-
sion levels and the clinicopathological parameters. 
As shown in Table  1, there were no significant corre-
lations between PDCD5 protein levels and age, myo-
metrial invasion, FIGO stage, estrogen receptor or 
progestin receptor. However, we found that the expres-
sion of PDCD5 was significantly associated with the 
degree of tumor differentiation (P < 0.05). PDCD5 pro-
tein levels were decreased in middle-low differentia-
tion of endometrioid endometrial carcinoma samples 
compared with high differentiation of endometrioid 
endometrial carcinoma samples (P  <  0.05) (Fig.  4d), 
which suggested that PDCD5 expression might be cor-
related with the progression of endometrioid endome-
trial carcinoma.
Fig. 3 Immunohistochemical staining for PDCD5 protein in endometrioid endometrial carcinoma and control endometrium (magnification, ×200, 
×400). a The immunostaining of PDCD5 protein in the proliferative phase of control endometrium; b the immunostaining of PDCD5 protein in the 
secretory phase of control endometrium; c the immunostaining of PDCD5 protein in high differentiation of endometrioid endometrial carcinoma 
tissues; d the immunostaining of PDCD5 protein in middle differentiation of endometrioid endometrial carcinoma tissues; e the immunostaining of 
PDCD5 protein in low differentiation of endometrioid endometrial carcinoma tissues; f negative control
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Discussion
PDCD5 was initially identified as a novel apoptosis-
related gene (Tracy et  al. 2014). Recent studies showed 
that PDCD5 might be a new tumor suppressor gene and 
involved in tumor development and progression (Xu 
et  al. 2012a). It has been reported that PDCD5 mRNA 
and protein were both downregulated in some human 
tumor tissues such as breast cancer (Hedenfalk et  al. 
2001), ovarian carcinoma (Gao et  al. 2015; Zhang et  al. 
2011), gastric cancer (Yang et  al. 2006), hepatocellular 
carcinoma (Xu et  al. 2001), acute and chronic myeloid 
leukemia (Ruan et  al. 2006), glioma (Li et  al. 2008) and 
laryngeal squamous cell carcinoma (Xu et al. 2013). How-
ever, it remains not very clear about PDCD5 expression 
in endometrial cancer. In the present study, we demon-
strated that PDCD5 protein expression was decreased 
in endometrioid endometrial carcinoma tissues com-
pared with control endometrium by western blot. How-
ever, unlike other tumors, PDCD5 mRNA levels had no 
apparent change between endometrioid endometrial car-
cinoma tissues and control endometrium.
To date, the regulation mechanisms of abnormal 
PDCD5 expression have not been fully clarified. Fernan-
dez et al. reported that bisphenol A exposure induced the 
downregulation of PDCD5 expression in human breast 
epithelial cells after accompanied by DNA methylation 
(Fernandez et  al. 2012). These data suggested that the 
abnormal expression of PDCD5 might be associated with 
DNA methylation. We speculate that the differences in 
PDCD5 mRNA and protein levels may be because the 
expression of PDCD5 could have post-transcriptional 
regulation in endometrioid endometrial carcinoma. 
However, the exact regulatory mechanism needs further 
exploration.
The endometrium is affected by ovarian hormones and 
undergoes proliferative, secretory and menstrual phase. 
These ovarian hormones including estrogen and proges-
terone could regulate the expression of some genes by 
Fig. 4 Statistical analysis of PDCD5 expression in 51 endometrioid endometrial carcinoma specimens and 53 control endometrium. a The staining 
index of PDCD5 in endometrial carcinoma specimens was significantly lower than that in control endometrium (P < 0.01); b No significant differ-
ences in PDCD5 expression were observed between proliferative phase and secretory phase of control endometrium (P > 0.05); c The staining index 
of PDCD5 in middle-low differentiation of endometrial carcinoma was significantly lower than that in control endometrium (P < 0.001), but there 
were no obvious differences between high differentiation of endometrial carcinoma and control endometrium; d The staining index of PDCD5 in 
high differentiation of endometrial carcinoma was significantly higher than that in middle-low differentiation of endometrial carcinoma (P < 0.05). 
*P < 0.05; **P < 0.01; ***P < 0.001
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hormone receptors. Ma et  al. reported that the expres-
sion of HOXA-10 was regulated by estrogen and pro-
gesterone in adult uterus. Progesterone could promote 
the expression of HOXA-10, but estrogen could inhibit 
its expression (Ma et  al. 1998). This explained the dif-
ference in HOXA-10 expression between proliferative 
phase and secretory phase of endometrium. To explore 
whether PDCD5 expression is also regulated by ovarian 
hormones, we compared the expression of PDCD5 in 
proliferative phase and secretory phase of control endo-
metrium. However, there were no significant differences 
between them. These results suggest that PDCD5 expres-
sion may not be regulated by ovarian hormones.
PDCD5 is a novel protein related to regulation of cell 
apoptosis, its expression level is significantly increased in 
cells undergoing apoptosis, and then the protein trans-
locates rapidly from the cytoplasm to the nuclei of cells 
(Chen et al. 2001; Li et al. 2016). The nuclear transloca-
tion of PDCD5 is a universal earlier event of the apoptotic 
process, and may be a novel early marker for apoptosis.
To explore the subcellular localization of PDCD5 in 
control endometrium and endometrioid endometrial car-
cinoma tissues, we detected PDCD5 expression by immu-
nohistochemistry analysis and found that PDCD5 staining 
mainly existed in the cytoplasm of the control endometrial 
glandular cells or endometrioid endometrial carcinoma 
cells, and weak PDCD5 expression was also observed in 
the nuclei of these cells. Immunocytochemistry analysis 
of control endometrial glandular cells and endometrioid 
endometrial carcinoma cell line KLE further confirmed 
these results. This is consistent with the report of Li et al., 
they found that PDCD5 was predominantly expressed in 
the cytoplasm of glioma cells, and a low level of PDCD5 
was also detected in the nuclei (Li et al. 2008).
Previous reports showed that the decreased expression 
of PDCD5 significantly correlated with the high-grade 
tumor in renal clear cell carcinomas (Tan et al. 2006) and 
gliomas (Li et  al. 2008). Moreover, the reduced expres-
sion of PDCD5 was related to short survival periods of 
patients with gastric cancer (Yang et al. 2006) and ovar-
ian serous carcinoma (Zhang et  al. 2011). These results 
suggest that PDCD5 is not only an apoptosis-related 
gene, but also a tumor suppressor.
In this study, we found that PDCD5 protein levels were 
not related to age, myometrial invasion, FIGO stage, 
estrogen receptor and progestin receptor of patients 
with endometrioid endometrial carcinoma. However, the 
expression of PDCD5 was significantly associated with 
Fig. 5 Immunocytochemical staining for vimentin, cytokeratin and PDCD5 protein in endometrial stromal cells, glandular epithelial cells and KLE 
cells (magnification, ×400). a The immunostaining of vimentin in endometrial stromal cells; b the immunostaining of cytokeratin in endometrial 
glandular epithelial cells; c the immunostaining of PDCD5 protein in endometrial glandular epithelial cells; d the immunostaining of PDCD5 protein 
in KLE cells
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the degree of tumor differentiation. The levels of PDCD5 
protein were downregulated in middle-low differen-
tiation of endometrioid endometrial carcinoma samples 
compared with high differentiation endometrioid endo-
metrial carcinoma samples. This may be the reason that 
PDCD5 protein was significantly lower in middle-low dif-
ferentiation of endometrioid endometrial carcinoma tis-
sues than that in control endometrium, but there was no 
significant difference in PDCD5 expression between high 
differentiation of endometrioid endometrial carcinoma 
tissues and control endometrium. Zhang et  al. reported 
that lost or decreased PDCD5 expression was associated 
significantly with FIGO stage in ovarian serous carci-
nomas (Zhang et  al. 2011) and Gao et  al. reported that 
the decreased expression of PDCD5 proteins was sig-
nificantly associated with the tumor size and mitosis of 
gastrointestinal stromal tumors (Gao et  al. 2012). The 
discrepancy may be due to clinicopathological character-
istics of different subjects.
Conclusion
In the current study, we found that PDCD5 protein was 
reduced in endometrioid endometrial carcinoma tis-
sues and its levels were associated with the degree of 
tumor differentiation. The results suggested that PDCD5 
expression might have an important role in the devel-
opment and progression of endometrioid endometrial 
carcinoma and might contribute to the improvement of 
prognosis. However, the detailed regulation mechanism 
of decreased PDCD5 expression in endometrioid endo-
metrial carcinoma requires further investigation.
Methods
Sample collection
Sixteen freshly frozen endometrioid endometrial carci-
noma tissues and 51 paraffin-embedded endometrioid 
endometrial carcinoma specimens were obtained from 
patients aged 44–74  years who underwent primary sur-
geries at Department of Gynecology and Obstetrics, 
Jinan Central Hospital affiliated to Shandong Univer-
sity from 2012 to 2014. The clinical stage was assessed 
according to the International Federation of Gynecology 
and Obstetrics (FIGO) system (2009). Tumor differen-
tiation degree, depth of myometrial invasion (MI), the 
expression of estrogen receptor (ER) and progestrone 
receptor (PR) were also evaluated. The basic characteris-
tics of endometrioid endometrial carcinoma patients are 
listed in Table 1. Seventeen freshly frozen control endo-
metrium tissues and 53 paraffin-embedded control endo-
metrial specimens were also collected from patients aged 
40–78 years who underwent uterine curettage for other 
diseases other than endometrial cancer. According to 
their menstrual history and histopathological examina-
tion, the control group was categorized as proliferative 
and secretory phases. This study and the collection of all 
human samples were approved by the Institutional Ethics 
Committee of Shandong University and all of the patients 
gave their informed consent.
RNA isolation and quantitative real‑time PCR (qRT‑PCR)
Total RNA was extracted from frozen tissues using a 
modified TRIzol (TIANGEN, Beijing, China) one-step 
extraction method. cDNA was synthesized using the 
FastQuant RT Kit (TIANGEN, Beijing, China) according 
to the manufacturer’s instructions. Quantitative real-time 
PCR was performed in 20 µL volume containing 10 µL of 
UltraSYBR Mixture (CWBIO, Beijing, China), 0.2  µL of 
cDNA, and 1  µL of primer (PDCD5 and GADPH). The 
sequences of the primers are as follows: PDCD5: sense, 
5′-GTT CTG GAT CAG TCG GCC C-3′, and antisense, 
5′-TCG TCA TCT TCA TCA GAG TCC A-3′; GAPDH: 
sense, 5′-AAC GGA TTT GGT CGT ATT GGG-3′, and 
antisense, 5′-CCT GGA AGA TGG TGA TGG GAT-3′. 
Polymerase chain reaction was performed according to 
the following programs: denatured at 95  °C for 10  min, 
and then followed by 39 cycles of 95 °C for 15 s, 60 °C for 
1 min and 65 °C for 5 s to stop the reaction. Each sample 
Table 1 Association analysis of PDCD5 expression in endo-











 ≤55 20 17 3 0.3359
 >55 30 28 2
Myometrial invasion (%)
 ≤50 31 27 4 0.8192
 >50 19 18 1
FIGO stage
 IA–IB 33 29 4 0.4861
 IC–II 17 16 1
Tumor differentiation degree
 High differentiation 11 8 3 0.0278*




 Negative-weak 11 10 1 0.7703
 Moderate-strong 31 29 2
Progestin receptor
 Negative-weak 11 10 1 0.7703
 Moderate-strong 31 29 2
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was conducted in triplicate. The results were analyzed 
using the 2 − ΔΔCt method.
Western blot analysis
The proteins were extracted from freshly frozen endome-
trioid endometrial carcinoma and control endometrium 
tissues using Radio Immunoprecipitation Assay (RIPA) 
buffer containing 1  % Phenylmethanesulfonyl fluoride 
(PMSF) and 0.5  % phosphatase inhibitor (PI). Then the 
bicinchoninic acid protein assay kit (Thermo Scientific, 
Rockford, IL, USA) was used to measure the protein con-
centrations. Each sample (40  µg) was analyzed by 15  % 
sodium dodecyl sulfate–polyacrylamide gel and then 
transferred onto a PVDF membrane. Then the membrane 
was blocked by 5  % bovine serum albumin for 2  h. The 
membrane was incubated overnight at 4  °C with 1:1000 
dillution of PDCD5 (Abcam, Shanghai, China) and 
β-actin (ZSJQB Co., Ltd. Beijing, China) antibodies fol-
lowed by horseradish peroxidase conjugated second anti-
bodies (1:2000 dilution, ZSJQB Co., Ltd. Beijing, China) 
for 1 h at room temperature. After washing, the signals 
were visualized by an ECL (Amersham Biosciences, Little 
Chalfont, UK) western blotting detection system accord-
ing to the manufacturer’s instruction. Western blot was 
performed at least three times for each sample.
Immunohistochemistry (IHC)
The paraffin sections (4  µm) were dewaxed and rehy-
drated by infiltrating in dimethylbenzene twice and 
graded ethanols. After antigen microwave retrieval and 
endogenous peroxidase blocking, the slides were blocked 
by 10 % goat serum for 15 min at 37 °C. Then the sections 
were incubated with 1:1000 dillution of PDCD5 antibody 
(abcam, Shanghai, China) overnight in a wet chamber 
at 4  °C followed by secondary antibody conjugated with 
horseradish peroxidase (ZSJQB Co., Ltd. Beijing, China) 
for 30 min at 37 °C. Then the expression of PDCD5 was 
visualized using diaminobenzidine (DAB) kit (Zsbio, 
Beijing, China) and the nuclei were counterstained with 
hematoxylin. Equal volume of PBS was used instead of 
PDCD5 antibody and served as a negative control. Each 
sample was performed in duplicate.
All IHC staining was analyzed by two experienced 
pathologists independently. The staining intensity was 
scored from 0 to 3 (0, no staining; 1, weak; 2, moderate; 3, 
strong). Based on the percentage of positive cells, the stain-
ing extent was scored from 0 to 4 (0, <1 %; 1, 1–10 %; 2, 
11–50 %; 3, 51–80 %; 4, 81–100 %). For each slide, the two 
scores were combined to produce a final grade of PDCD5 
expression: 0 (−), 1–3 (+), 4 and 6 (++), 8 and 9 (+++), 12 
(++++). The expression of PDCD5 was defined as follows: 
−, + and ++ were classified as low and middle expression, 
whereas +++ and ++++ was graded as high expression.
The isolation of glandular epithelial cells and stromal cells 
derived from control endometrium
The glandular epithelial cells and stromal cells derived 
from secretory phase of control endometrium were iso-
lated according to the method described previously 
(Sugawara et  al. 1997) with slight modifications. Briefly, 
the endometrial tissues were suspended in a sterile tube 
containing DMEM/F12 1:1 (HyClone Corporation, 
Beijing, China), 10  % FBS (Gibco, CA, USA), 100 U/ml 
of penicillin and 100  U/ml of streptomycin. And then 
the specimens were minced and digested in 0.25  % col-
lagenase type IA (Gibco, CA, USA) at 37  °C in a shak-
ing water bath for about 50  min. Two to three volumes 
of pre-warmed culture medium was used to stop the 
collagenase activity. The cell suspension was succes-
sively filtered through a 154-mm monofilament cupre-
ous mesh and a 38.5-mm monofilament cupreous mesh. 
The filtrate containing stromal cells was collected and 
centrifuged at 1000  rpm/min for 10  min, the pellet was 
resuspended and incubated in 24-well plates with cover 
slips at 2.5 × 105 cells/well at 37 °C in 95 % air and 5 % 
CO2. To remove the non-attached cells, the culture 
medium was replaced with fresh medium 2 h later. The 
38.5 mm monofilament cupreous mesh was washed thor-
oughly upside down with culture medium, then the cell 
suspension containing glandular epithelial cells was col-
lected and centrifuged at 1000 rpm/min for 10 min. The 
pellet was resuspended and incubated in 24-well plates 
with cover slips at 5 × 104 cells/well at 37 °C in 95 % air 
and 5 % CO2.
Immunocytochemistry (ICC)
The human endometrioid endometrial carcinoma cells 
(KLE, low differentiation) were purchased from China 
Center for Type Culture Collection (Wuhan, China) and 
cultured in DMEM/F12 1:1 (HyClone Corporation, Bei-
jing, China) containing 10 % fetal bovine serum (Gibco, 
CA, USA), 100 U/ml of penicillin and 100 U/ml of strep-
tomycin. The cells were seeded in 24-well plates with 
cover slips at 5 × 104 cells/well at 37 °C in 95 % air and 
5 % CO2. After the glandular epithelial cells, stromal cells 
and KLE cells were cultured in 24-well plates with cover 
slips overnight, the cells on the cover slip were fixed with 
4  % paraformaldehyde for 30  min. After successively 
endogenous peroxidase blocking and 10  % goat serum 
blocking, the cells were respectively incubated with anti-
human antibodies against vimentin (1:100) (ZSJQB Co., 
Ltd. Beijing, China), cytokeratin (1:100) (ZSJQB Co., Ltd. 
Beijing, China) and PDCD5 (1:1000) (abcam, Shanghai, 
China) overnight at 4  °C. The cells were washed with 
PBS and incubated with horseradish peroxidase-con-
jugated secondary antibodies (ZSJQB Co., Ltd. Beijing, 
China) for 30 min at 37 °C. Then the protein expression 
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was visualized using diaminobenzidine (DAB) kit (Zsbio, 
Beijing, China) and the nuclei were counterstained with 
hematoxylin. Each sample was performed in duplicate.
Data analysis
The unpaired Student’s t test was used to analyze the 
expression of PDCD5 detected by qRT-PCR. The Gel-Pro 
analyzer was used to detect the grey value of the bands 
of PDCD5 expression detected by western blot, and then 
the unpaired Student’s t test was used for analysis. The 
immunohistochemical data was analyzed using chi2 test. 
And the GraphPad Prism 5 (GraphPad Software Inc., 
CA, USA) was used for statistical analysis. All data were 
expressed as mean ± SEM. P < 0.05 was considered sta-
tistically significant.
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